KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Edwards Lifesciences (EW) EBIAT (2016 - 2025)

Edwards Lifesciences has reported EBIAT over the past 17 years, most recently at $91.2 million for Q4 2025.

  • Quarterly results put EBIAT at $91.2 million for Q4 2025, down 76.27% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 74.31% YoY), and the annual figure for FY2025 was $1.1 billion, down 23.1%.
  • EBIAT for Q4 2025 was $91.2 million at Edwards Lifesciences, down from $292.3 million in the prior quarter.
  • Over the last five years, EBIAT for EW hit a ceiling of $3.1 billion in Q3 2024 and a floor of $91.2 million in Q4 2025.
  • Median EBIAT over the past 5 years was $347.2 million (2022), compared with a mean of $481.0 million.
  • Biggest five-year swings in EBIAT: skyrocketed 816.93% in 2024 and later plummeted 90.48% in 2025.
  • Edwards Lifesciences' EBIAT stood at $335.3 million in 2021, then rose by 18.82% to $398.4 million in 2022, then dropped by 7.2% to $369.7 million in 2023, then rose by 3.95% to $384.3 million in 2024, then tumbled by 76.27% to $91.2 million in 2025.
  • The last three reported values for EBIAT were $91.2 million (Q4 2025), $292.3 million (Q3 2025), and $331.5 million (Q2 2025) per Business Quant data.